Chronic Inflammatory Demyelinating Polyneuropathy Market

Global Chronic Inflammatory Demyelinating Polyneuropathy market is valued at US$ 1.39 Billion in 2022 and expected to reach USD US$ 2.84 Billion by 2029 with a CAGR of 10.8% over the forecast period.

Global Chronic Inflammatory Demyelinating Polyneuropathy Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2023-2029- Rising prevalence of chronic inflammatory demyelinating polyneuropathy, growing government support for drug approval and increasing incidences of harmful habits are some of the major factors driving the growth of Global Chronic Inflammatory Demyelinating Polyneuropathy Market.

Scope of Global Chronic Inflammatory Demyelinating Polyneuropathy Market Report-

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder leading to weakness and loss of sensation in the legs and arms. It occurs because of the inappropriate reaction of the body’s immune system and damaging myelin sheath. Myelin sheath surrounds the peripheral nervous system and acts as an insulator for the nerves to conduct impulses properly. CIDP is caused by an abnormal immune response. CIDP happens when the immune system assaults the myelin cover of the nerves. Hence, CIDP is believed to be an immune system disease.

Medical services suppliers likewise think about CIDP as the constant type of Guillain-Barré syndrome. Side effects of chronic inflammatory demyelinating polyneuropathy (CIDP) incorporates shivering, numbness, or adjusted feeling, which frequently starts in hands and feet weakness in arms and legs, muscle pain, fatigue, and others. Chronic inflammatory demyelinating polyneuropathy (CIDP) is more noticeably seen in men than in ladies.

The Covid-19 pandemic had a negative impact on the global chronic inflammatory demyelinating polyneuropathy market. The pandemic has disrupted healthcare systems worldwide, leading to delays in diagnosis, treatment initiation, and follow-up care for CIDP patients. The focus of healthcare resources has shifted towards managing Covid-19 cases, resulting in reduced access to healthcare facilities and specialists for CIDP patients.

Additionally, clinical trials and research activities related to CIDP may have been affected. However, the long-term impact on the CIDP market is yet to be fully understood, and efforts are being made to ensure continuity of care and minimize the impact on patients' outcomes.

Global chronic inflammatory demyelinating polyneuropathy market is segmented on the basis of treatment, diagnosis method, route of administration, end-users and region & country level. Based on the treatment, the global chronic inflammatory demyelinating polyneuropathy market is classified into corticosteriods, intravenous immunoglobulin, physiotherapy, plasmapheresis, and others. Based on the diagnosis method, the market is classified into nerve conduction, EMG, spinal fluid analysis, electrodiagnostic testing, and others. Based on the route of administration, the global chronic inflammatory demyelinating polyneuropathy market is classified into oral, intravenous, and others. Based on the end-users, the market is classified into research and academic laboratories, specialty neurological clinics, hospitals, and others.

The regions covered in global chronic inflammatory demyelinating polyneuropathy market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global chronic inflammatory demyelinating polyneuropathy is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc.

Key Players for Global Chronic Inflammatory Demyelinating Polyneuropathy Market Report-

Some major key players in the global chronic inflammatory demyelinating polyneuropathy market report cover prominent players like -

• Takeda Pharmaceutical Co. Ltd.
• CSL Behring
• Kedrion S.p.A.
• Shire Plc.
• Baxter International Inc.
• Teijin Pharma Ltd.
• Nihon Pharmaceutical Co. Ltd.
• GeNeuro SA
• Octapharma AG
• Grifols S.A.
• Teva Pharmaceutical Industries Ltd.
• Hoffmann-La Roche Ltd.
• other

Global Chronic Inflammatory Demyelinating Polyneuropathy Market Segmentation:-

By Treatment:

• Corticosteriods
• Intravenous Immunoglobulin
• Physiotherapy
• Plasmapheresis
• Others

By Diagnosis Method:

• Nerve Conduction
• EMG
• Spinal Fluid Analysis
• Electrodiagnostic Testing
• Others

By Route-of-Administration:

• Oral
• Intravenous
• Others

By End-User:

• Research and Academic Laboratories
• Specialty Neurological Clinics
• Hospitals
• Others

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Rising prevalence of Chronic Inflammatory Demyelinating Polyneuropathy, Growing Government Support for Drug Approval and Increasing Incidences of Harmful Habits are Some of the Major Factors Driving the Market Growth

One of the major factors driving the growth of the global chronic inflammatory demyelinating polyneuropathy market is the rising prevalence of chronic inflammatory demyelinating polyneuropathy. For example; according to GBS/CIDP Foundation International The occurrence of CIDP every year is projected to be somewhere in the range of 1.5 and 3.6 million in the populace. The quantity of new cases each year of chronic inflammatory demyelinating polyneuropathy (CIDP) is around 1-2 for every 100,000 individuals, yet as the disease can be available in an individual for years prior to diagnosis, the prevalence mirroring the gathering of cases after some time might be basically as high as 9 for every 100,000 in certain areas.

In addition, growing government support for drug approval is also supplementing the market growth. Increasing awareness about rare neurological diseases government gives approval for novel drug development which further drives the chronic inflammatory demyelinating polyneuropathy market. For example; as per the news published on February 12^th, 2021; U.S. FDA approved PANZYGA for the therapy of grown-ups with constant provocative demyelinating polyneuropathy (CIDP). PANZYGA is the key intravenous immunoglobulin (IVIg) with two FDA- approved maintenance dosing choices for CIDP, assisting with meeting the clinical needs of patients.

Furthermore, the increasing incidences of harmful habits also drives the global traffic management market. The rise in the rate of harmful habits like unreasonable smoking, unnecessary sedentariness, and exorbitant utilization of contaminations present in the air in urban centers has brought about a developing frequency of immune system diseases throughout recent years. The developing commonness of such habits is probably going to stay a key driver global chronic inflammatory demyelinating polyneuropathy market over the forecast period.

For example; according to the Global Adult Tobacco Survey (GATS), in 2018, around 8 million individuals worldwide die from smoking every year, and over 80% of the 1.3 billion tobacco clients overall live in low- and middle-income countries. However, the presence of limited treatment options & high cost of approved drugs may hamper the global chronic inflammatory demyelinating polyneuropathy market growth.

In spite of that, the increasing technological advancement in drug development can provide various opportunities for the further growth of the global chronic inflammatory demyelinating polyneuropathy market.

North America is Expected to Dominate the Global Chronic Inflammatory Demyelinating Polyneuropathy Market

North America is expected to dominate the global chronic inflammatory demyelinating polyneuropathy market due to the growing incidences of chronic inflammatory demyelinating polyneuropathy, rising government initiatives and other organizations and advancements in technology in this region. For instance; as per the CIDP Foundation International chronic inflammatory demyelinating polyneuropathy (CIDP) influences around 8.9% per 100,000 individuals each year in North America.

Also, rising initiatives from governments and other organizations also drive the growth of chronic inflammatory demyelinating polyneuropathy market over the forecast period. For example; in 2019, UCB S.A started stage 2 clinical preliminaries for Rozanolixizumab for the therapy of patients with chronic inflammatory demyelinating polyneuropathy.

Europe is anticipated to grow faster in the global chronic inflammatory demyelinating polyneuropathy market within the forecast period due to rising smoking habits and growing urbanization. For instance; according to the Global Adult Tobacco Survey (GATS), there are in excess of 300 million smokers in China, with 52.9% of Chinese male adults smoking, in 2018.

News-

U.S. FDA Approved PANZYGA for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

On February 12^th, 2021; Pfizer Inc. announced that the U.S. Food and Medication Organization (FDA) endorsed the supplemental Biologics License Application (sBLA) for PANZYGA (Immune Globulin Intravenous [Human] - ifas 10% Liquid Preparation) to treat grown-up patients with an intriguing neurological infection of the fringe nerves called chronic inflammatory demyelinating polyneuropathy (CIDP). PANZYGA is the main intravenous immunoglobulin (IVIg) with two FDA- approved maintenance dosing choices for CIDP, assisting with meeting the clinical requirements of patients. PANZYGA can likewise be regulated at mixture rates up to 12 mg/kg/min.

argenx Announced “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

On February 1^st, 2021; argenx SE announced its arrangement to proceed with enlistment in the ADHERE trial assessing subcutaneous (SC) Efgartigimod (co-figured out with Halozyme's ENHANZE drug-delivery innovation) in chronic inflammatory demyelinating polyneuropathy (CIDP). The ADHERE trial is supposed to enlist around 130 patients to help the expected enrollment of SC Efgartigimod for the treatment of CIDP. The "GO" choice depended on an arranged viability and security evaluation following the enlistment of 30 patients into the initial part of the ADHERE trial. The break examination accomplished the pre-characterized edge for continuation, which depended on reaction rates found in point of reference clinical trials of the current standard of care in CIDP.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2022:	USD 1.39 Billion
Base year considered	2021
Forecast Period CAGR %:	10.8%
Market Size Expected in 2029:	USD 2.84 Billion
Tables, Charts & Figures:	175
Pages	300
Companies	Takeda Pharmaceutical Co. Ltd., CSL Behring, Kedrion S.p.A., Shire Plc., Baxter International Inc., Teijin Pharma Ltd., Nihon Pharmaceutical Co. Ltd., GeNeuro SA, Octapharma AG and Grifols S.A., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd. and other
Segments Covered	By Treatment, By Diagnosis Method, By Route-of-Administration, By End-User
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa.